The peptide research universe, mapped.
Compound Universe Genome translates complex peptide science into clear, evidence-tiered research profiles—separating human outcomes, animal findings, laboratory mechanisms, safety signals, and regulatory facts.
What CU-Genome is
A navigable genome of peptide evidence.
Compound Universe Genome, abbreviated as CU-Genome, is an independent informational research project covering peptides, peptide therapeutics, signaling compounds, and related investigational molecules.
The project maps the complete evidence chain behind each compound: molecular target, proposed mechanism of action, study model, human clinical outcomes, adverse events, approval status, and the questions science has not yet answered.
CU-Genome does not treat biological plausibility as clinical proof. A laboratory mechanism, an animal experiment, a controlled human trial, and a regulatory decision represent different kinds of evidence—and they are presented that way.
The research landscape
Peptide science across biological systems
CU-Genome organizes peptide research by biological system and study objective. These topic areas connect mechanisms, individual compounds, experimental models, clinical findings, safety data, and regulatory context.
Healing and recovery
BPC-157, thymosin beta-4–related research, tissue repair, tendon models, wound healing, angiogenesis, and gastrointestinal studies.
Weight and metabolism
GLP-1, GIP, and glucagon receptor agonism, obesity trials, glycemic control, appetite signaling, and body-composition outcomes.
Skin and hair
GHK-Cu, copper peptides, collagen, extracellular-matrix biology, skin remodeling, wound response, and hair research.
Muscle and performance
Growth-hormone secretagogues, GHRH analogs, lean mass, exercise physiology, recovery, and performance-related evidence.
Brain, sleep, and cognition
Peptide research involving neurological pathways, cognition, mood, circadian biology, neuroprotection, and sleep.
Immune and inflammation
Thymic peptides, immune signaling, inflammatory pathways, host defense, cellular repair, and preclinical models.
Sexual health
Melanocortin signaling and peptide studies related to sexual desire, arousal, reproductive biology, and function.
Aging and longevity
Experimental compounds, cellular senescence, mitochondrial biology, aging pathways, lifespan models, and translational limits.
Compound knowledge base
Widely researched and discussed peptides
The peptide landscape includes approved medicines, discontinued drugs, clinical-stage candidates, naturally occurring peptides, synthetic analogs, and research-only compounds. Their evidence and legal status are not interchangeable.
Evidence is not one thing
Different studies answer different questions.
CU-Genome classifies claims according to the type and maturity of the underlying evidence. This prevents an effect observed in isolated cells or rodents from being presented as an established human outcome.
Experiments in cells, tissues, or isolated biological systems that can explore mechanisms but cannot establish a clinical effect.
Preclinical models that may identify biological signals, safety concerns, or therapeutic hypotheses requiring human validation.
Observational studies, pharmacology research, and controlled clinical trials, evaluated according to design and outcome quality.
Approval labels, safety communications, compounding decisions, and other legal documents dated to their jurisdiction.
Research beyond efficacy
Mechanisms, comparisons, safety, and status
Useful peptide research requires more than listing potential benefits. CU-Genome places biological findings inside a broader framework that includes evidence quality, pharmacology, safety, legality, and clinical relevance.
How peptides interact with biology
Receptor activity, signaling pathways, half-life, bioavailability, metabolism, and the difference between a plausible mechanism and a demonstrated outcome.
Like-for-like evidence
Compounds are compared by molecular target, study population, evidence maturity, measured outcomes, safety information, and regulatory position.
Status with a date and jurisdiction
FDA approval, compounding eligibility, prescribing rules, research status, and sporting restrictions are separate questions and can change over time.
The CU-Genome editorial standard
Evidence before excitement.
Every research summary is designed to show not only what a study reports, but also how much confidence that study deserves and what it cannot establish.
Start with primary literature
Original research, trial registries, PubMed records, DOIs, approved labels, and regulator documents take priority over commercial summaries.
Label the evidence
Laboratory, animal, observational, controlled human, systematic-review, and regulatory evidence are identified separately.
Report the limitations
Small samples, weak controls, surrogate outcomes, conflicts, absent replication, and missing long-term safety data remain visible.
Date material updates
New trials, approvals, safety communications, and regulatory decisions are incorporated with a visible review date.